Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Hence, VIVUS's Capex-to-Operating-Cash-Flow for the
three
months ended in Mar. 2020 was 0.00.
VIVUS Capex-to-Operating-Cash-Flow Historical Data
The historical data trend for VIVUS's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of VIVUS's Capex-to-Operating-Cash-Flow
For the Biotechnology subindustry, VIVUS's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VIVUS's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VIVUS's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where VIVUS's Capex-to-Operating-Cash-Flow falls into.
VIVUS Capex-to-Operating-Cash-Flow Calculation
VIVUS's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
VIVUS Capex-to-Operating-Cash-Flow Related Terms
Thank you for viewing the detailed overview of VIVUS's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:VIU1 has been successfully added to your 